TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares

TScan Therapeutics, Inc. (NASDAQ:TCRX) major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the stock in a transaction dated Friday, December 19th. The shares were acquired at an average cost of $0.90 per share, with a total value of $72,062.10. Following the acquisition, the insider directly owned 7,937,416 shares in the company, valued at $7,143,674.40. This represents a 1.02% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Lynx1 Capital Management Lp also recently made the following trade(s):

• On Tuesday, December 23rd, Lynx1 Capital Management Lp bought 6,232 shares of TScan Therapeutics stock. The stock was acquired at an average price of $0.90 per share, for a total transaction of $5,608.80.
• On Monday, December 22nd, Lynx1 Capital Management Lp bought 75,500 shares of TScan Therapeutics stock. The stock was bought at an average cost of $0.90 per share, with a total value of $67,950.00.

TScan Therapeutics Price Performance

TCRX stock traded up $0.01 during trading on Tuesday, reaching $0.91. 342,212 shares of the company were exchanged, compared to its average volume of 538,535. The company has a market capitalization of $51.68 million, a price-to-earnings ratio of -0.81 and a beta of 1.04. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. The company has a 50-day moving average of $1.37 and a two-hundred day moving average of $1.63. TScan Therapeutics, Inc. has a twelve month low of $0.88 and a twelve month high of $3.43.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. The company had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. As a group, equities analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Voleon Capital Management LP bought a new position in shares of TScan Therapeutics during the 3rd quarter worth approximately $87,000. Citadel Advisors LLC lifted its position in shares of TScan Therapeutics by 78.4% during the 3rd quarter. Citadel Advisors LLC now owns 390,747 shares of the company’s stock valued at $711,000 after acquiring an additional 171,760 shares during the period. Virtu Financial LLC boosted its stake in TScan Therapeutics by 431.1% during the third quarter. Virtu Financial LLC now owns 60,480 shares of the company’s stock worth $110,000 after acquiring an additional 49,092 shares in the last quarter. Two Sigma Investments LP boosted its stake in TScan Therapeutics by 14.9% during the third quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock worth $763,000 after acquiring an additional 54,370 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in TScan Therapeutics by 7.8% in the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock worth $4,219,000 after purchasing an additional 168,540 shares during the period. 82.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TCRX has been the subject of several analyst reports. HC Wainwright dropped their price target on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Morgan Stanley lowered TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Wednesday, October 8th. Finally, Needham & Company LLC lowered their price objective on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.60.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.